With its first two repurposed products now in the clinic, e-Therapeutics plc is branching out into drug discovery using the same systems biology platform that helped it identify its clinical-stage compounds.

The platform is built upon the theory of network pharmacology, which suggests compounds should be designed to affect multiple nodes in a network of targets that work together to drive a given cellular process.